On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Local 100 members build new pavilions for scouts in Whiteford, Md.
- Stand by Our Brother: Support Jesus Mesina and His Family
- General President Coleman’s statement on White House budget office encouraging the use of project labor agreements
- Arkansas & Missouri Begins a New Chapter with SMART-TD
- General President Coleman’s statement on the Department of Energy canceling $3.7 billion in funding awards for energy projects
- Montebello Transit Wins Longevity Pay, Wage Gains
- Education Department helps unionists strengthen advocacy in Pittsburgh
- Representative Paul Evans Sells Out Oregon Railroaders
- SMART General President Michael Coleman’s statement on reports that Kilmar Abrego Garcia will return to the United States
- PHOTO GALLERY: SEPTA Drivers Provide Bulletproof Barrier Feedback